natgillin/translations-raw huggingface dataset:
H-Asp(O-P2)-Trp-Pro-OH through attachment of the Gly residue of the 2-3 eptifibatide fragment to the Asp residue of the 4-6 eptifibatide fragment, thereby forming the 2-6 eptifibatide fragment. 
H-Asp(O-P>)-Trp-Pro-OH preko vezivanja Gly ostatka fragmenta 2-3 eptifibatida na Asp ostatak fragmenta 4-6 eptifibatida, da na taj način nastane fragment 2-6 eptifibatida.
A compound, or a hydrate, a solvate, a salt thereof of Formula (IV) 
Spoj ili hidrat, solvat, ili njihova sol naznačeni time da imaju formulu (TV).
The method of claim 2, wherein the plurality of types of transaction diagnostic blocks comprises: a program-specified TDB specified by a transaction begin instruction, a program interruption TDB to be used for aborts due to an interruption, and an interception TDB to be used for aborts due to an interception. The method of claim 2, wherein the checking indicates a plurality of transaction diagnostic blocks are to be stored into based on the abort. 
Računalni programski proizvod u skladu s patentnim zahtjevom 2, naznačen time što više tipova blokova za dijagnosticiranje sadrži: programski specificirani blok za dijagnosticiranje transakcije kojeg specificira neograničena uputa o početku transakcije, blok za dijagnosticiranje transakcije namijenjen prekidanju programa, koji treba upotrijebiti za obustavu zbog prekida, te presretački blok za dijagnosticiranje transakcije, koji treba upotrijebiti za prekidanje zbog bilo kojeg stanja izuzimanja programa koje rezultira presretanjem.
A method according to any preceding claim, wherein the mineral fibres and binder, when suspended in the primary air flow, are subjected to a further air flow in a different direction to the primary air flow. 
Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, pri čemu se ta mineralna vlakna 1 vezivno sredstvo, kada lebde u primarnom protoku zraka, podvrgavaju daljem protoku zraka u različitom smjeru u odnosu na primarni protok zraka.
The liquefied gas treatment system according to claim 1, further comprising a forcible vaporizer (31) configured to forcibly vaporize the liquefied natural gas stored in the storage tank (11) and supply the vaporized liquefied natural gas to the compressor (13,13a,13b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži prisilni isparivač, podešen za prisilno isparavanje LNG spremljenog u spremniku za teret i slanje prisilno isparenog LNG u kompresor.
(viii) binding to an epitope located on domain I of ErbB3; and/or 
(vili) vezivanje za epitop lociran na domenu I od ErbB3; i/ili
A process for making treprostinil (18) according to claim 2 comprising the following steps: 
H 3. > Postupak za pripremu treprostinila (18) prema patentnom zahtjevu 2 koji sadrži sljedeće korake: s
The pharmaceutical composition of claim 1, wherein the second lipid nanoparticle comprises a second encapsulated polynucleotide that is (i) identical to the mRNA in the first lipid nanoparticle or (ii) not identical to the mRNA in the first lipid nanoparticle. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time da druga lipidna nanočestica sadrži RNK koja je (1) identična iRNK u prvoj lipidnoj nanočestici ili (11) nije identična iRNK u prvoj lipidnoj nanočestici.
The antisense oligonucleotide as defined in any one of claims 1-14, the vector of claim 15, or the pharmaceutical composition of claim 16, for inducing or promoting exon 45 skipping, optionally in combination with skipping of one of the exons 7, 44, 46, 51, 53, 59, 67, in the dystrophin pre-mRNA for use in treating a DMD or a BMD patient. 
Besmisleni oligonukleotid u skladu s bilo kojim od patentnih zahtjeva 1-14, vektor iz patentnog zahtjeva 15, ili farmaceutski sastav iz patentnog zahtjeva 16, za induciranje ili promoviranje preskakanja eksona 45 za uporabu u liječenju pacijenta s DMD ili BMD. Farmaceutski sastav iz patentnog zahtjeva 17 za preskakanje najmanje dva ciljna eksona iz pre-mRNA distrofina, poželjno za preskakanje cijelog područja između navedena dva ciljna eksona navedene pre-mRNA za uporabu u liječenju pacijenta s DMD ili BMD.
the double-stranded short interfering nucleic acid (siNA) of claim 1; a cationic lipid; 
(a) molekulu s dvolančanom kratkom interferirajućom nukleinskom kiselinom (siNA) u skladu s patentnim zahtjevom 1; (b) _kationski lipid;
The fluid outlet may be in contact with said open distal end of the tubular member via an interior passage extending longitudinally in said tubular member. 
Izlazni otvor za fluid može biti u kontaktu s navedenim udaljenijim krajem cijevnog elementa preko unutarnjeg prolaza koji se prostire uzdužno u navedenom cijevnom elementu.
Substitution variants preferably involve the replacement of one or more amino acids with the same number of amino acids and making conservative amino acid substitutions. 
(a) varijanta je polipeptid koji se sastoji od dvije ili više konzervativne supstitucije aminokiselina u usporedbi sa zamijenjenim peptidom, ili
Brine (10 mL) is added to it and extracted with tetrahydrofuran (3x15 mL). 
Tome se doda slana voda (10 ml), te ekstrahira tetrahidrofuranom (3 x 15 ml).
The composition for use of claim 1, wherein the polypeptide consists essentially of the amino acid sequence of SEQ ID NO: 4. 
Polipeptid prema patentnom zahtjevu 8, naznačen time što dvolančani polipeptid sadrži aminokiselinsku sekvencu koja ima najmanje 95% homologije sa SEQ ID NO:13.
—X wherein X is selected from the group consisting of F, Cl, Br and I; 
(g) -X gdje se X bira iz skupine koju čine F, Cl, Bri L;
Composition according to claim 1 comprising an amount of a zinc salt effective for increasing the pH of the gastric juices of the stomach of a patient to a pH of at least about 3 within a period of no greater than one hour. 
Pripravak za uporabu prema zahtjevu 1 ili 2 gdje je ta količina cinkove soli učinkovita da podigne pH želučanih sokova u želucu tog bolesnika na barem 4.0.
Another embodiment of the present invention is a combination of an M3 antagonist which is 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, with a LABA selected from formoterol, salmeterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149. 
Sljedeće utjelovljenje predmetnog izuma je kombinacija M3 antagonista, koji je spoj 3(R)-(2-hidroksi-2,2-ditien-2- ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo[2.2.2]oktan bromid s kortikosteroidom odabranim između sljedećeg: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid 1 flutikazon propionat.
An anti-CSF-1R antibody having a heavy chain comprising the sequence given in SEQ ID NO:27 and a light chain comprising the sequence given in SEQ ID NO:19. 
Anti-CSF-1R antitijelo koje ima teški lanac naznačeno time da sadrži sekvencu danu u SEK ID BR: 27 i laki lanac koji sadrži sekvencu danu u SEK ID BR: 19.
The capsule of claim 12 wherein the alkalizing agent is one of meglumine, calcium carbonate, sodium sulfate, sodium bicarbonate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 16, naznačena time što se alkalizirajuće sredstvo sastoji od meglumina, kalcijeva karbonata, natrijeva sulfata, natrijeva bikarbonata ili kombinacija navedenog.
recycling said second organic solvent after said stripping of said extracted phosphoric acid to be used for said step of extracting phosphoric acid; said second organic solvent has a concentration of tributyl phosphate between 70 and 100% by volume; 
recikliranje (284) spomenutog drugog organskog otapala nakon spomenutog uklanjanja spomenute ekstrahirane fosforne kiseline kako bi se koristilo za spomenuti korak ekstrahiranja fosforne kiseline; spomenuto drugo organsko otapalo ima koncentraciju tributil fosfata između 70 i 100 % volumena;
The formulation according to claim 14 wherein said formulation is a suppository or a vaginal ovule and comprises between 80% and 99% by weight of said composition. The formulation in the form of a suppository or vaginal ovule according to claim 15 wherein said composition consists of 5 to 17 parts by weight of beeswax, 5 to 25 parts by weight of honey, and 65 to 90 parts by weight of cocoa butter for a total of 100 parts by weight. 
Formulacija u skladu s patentnim zahtjevom 14, naznačena time, da je navedena formulacija supozitorij ili vaginaleta i sadržava između 80 % 199 % težine navedenog pripravka, Formulacija u obliku supozitorija ili vaginalete u skladu s patentnim zahtjevom 15, naznačena time, da se navedeni pripravak sastoji od 5 do 17 težinskih udjela pčelinjeg voska, 5 do 25 težinskih udjela meda 1 65 do 90 težinskih udjela kakao maslaca od ukupno 100 težinskih udjela .
a solution of clopidogrel base in a solvent is provided, wherein the solvent is a mixture of ethyl acetate with methylene chloride which comprises up to 10 % by weight of methylene chloride, 
otopina baze klopidogrela se dobiva u otapalu, pri čemu je otapalo smjesa etilacetata s metilenkloridom, koja sadrži do 10 masenih % metilenklorida,
A self-propelled working machine according to claim 6, when depending to claim 4 or 5, wherein said axis of rotation (12) is arranged in a radially inner portion of the step board (11). 
Radni stroj na vlastiti pogon u skladu sa patentnim zahtjevom 3 i patentnim zahtjevom 4, pri čemu je navedena os (12) rotacije postavljena u radijalno unutrašnjem dijelu gazišta (11) stepenice.
The compound or salt thereof can further be used in combination with an anti-obesity agent including but not limited to a glucagon-like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist. 
(b) sredstvo za liječenje pretilosti je agonist receptora 1 peptida nalik na glukagon, peptid YY ili njegov analog, antagonist receptora 1 kanabinoida, inhibitor lipaze, agonist receptora 4 melanokortina ili antagonist receptora 1 hormonske koncentracije melanina.
wherein ring A is a benzene ring which is optionally further substituted; 
= i or ill gdje prsten A je benzen-prsten koji je opcijski dodatno supstituiran;
A water-soluble solid ferric pyrophosphate citrate chelate composition comprising: 
U vodi topljiva čvrsta smjesa kelata feri-pirofosfat citrata koja sadrži:
A compound having the formula (I), or a pharmaceutically-acceptable salt, prodrug, solvate, isomer, and/or hydrate thereof, wherein: 
Spoj formule (I), [image] ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili hidrat, naznačen time što:
A porous substrate according to claim 4, wherein said DNAzyme sequence is enlarged with foreign nucleotide domain having a free conformation and an active conformation upon associating with at least one second analyte; wherein said active conformation of said DNAzyme sequence is capable of forming a cleavage-prone conformation upon association with said at least one first analyte thereby enabling cleavage of said capping nucleic acid sequence, and allowing the release of said embedded at least one active agent. 
Porozni supstrat sukladno zahtjevu 4, pri čemu je DNAzyme sekvenca povećana domenom stranog nukleotida slobodne konformacije i aktivne konformacije nakon spajanja s barem jednim sekundarnim analitom; pri čemu je aktivna konformacija DNAzyme sekvence sposobna formirati konformaciju sklonu cijepanju nakon spajanja s barem jednim prvim analitom omogućavajući cijepanje preklopnog niza nuleinske kiseline, i omogućavajući otpuštanje barem jednog aktivnog agensa unutar.
A medicament comprising a compound as claimed in any of claims 1 to 9. The use of a compound as claimed in any of claims 1 to 9 for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases. 
Upotreba spoja temeljem bilo kojeg od zahtjeva 1 do 10, njegovog tautomernog oblika, enantiomernog oblika, dijastereomernog oblika i/ili fiziološki tolerirane soli za pripremu lijeka za liječenje i/ili profilaksu različitih bolesti ovisnih o vazopresinu i oksitocinu.
In a preferred embodiment of the process according to the invention, the Group II or Group III salt(s) of an aliphatic carboxylic acid salt employed in step (a) are selected so as to feature a viscosity of more than 100 000 mPas, and preferably of more than 1 000 000 mPas, at 180° C. measured in a PHYSICA MCR 300 equipped with a CP50-1 instrumentation at a shear rate of 5 s(−1) and scanning temperatures from 200 to 130° C. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time da sol odnosno soli Skupine II ili Skupine III C8 do C24 alifatske monokarboksilne kiseline koja se koristi u koraku (a) su odabrane tako da imaju viskoznost od više od 100 000 mPas, te poželjno od više od 1 000 000 mPas, kod 180 *C mjereno sa PHYSICA MCR 300 opremljenim sa CP50-1 instrumentima uz smičnu brzinu od 5 s" i temperature skeniranja od 200 to 130 *C,
• conveying the conditioned preform to a blow mold station at a rate such that the temperature of the surface of the preform does not decrease more than 5° C.; 
PET posuda iz patentnog zahtjeva 9 gdje je temperatura drugog endotermnog prelaza stakla najmanje 30° C. viša nego temperatura prvog endotermnog prelaza stakla.
a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder, preferably a HER2-positive cancer, and more preferably a HER2-positive breast cancer or a HER2-positive gastric cancer. 
prilog pakiranju koji sadrži upute za primjenu pripravka kod pojedinca u svrhu liječenja ili odgađanja progresije poremećaja stanične proliferacije, poželjno HER2 pozitivnog raka, i još poželjnije HER2 pozitivnog raka dojke ili HER2 pozitivnog raka želuca.
is a straight or branched (C1-C4) alkyl group; 
R, je narazgranata ili razgranata (C;-C,) alkilna skupina;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
The combination of claim 18 wherein the HCV antiviral agent is an HCV protease inhibitor or an HCV NS3B polymerase inhibitor. 
Kombinacija prema patentnom zahtjevu 16, naznačena time što je antivirusno sredstvo inhibitor HCV proteaze ili inhibitor HCV NS5B polimeraze.
Habituation. Rats are allowed to habituate to the empty test box and the behavioural test room environment for 1 hour on day 1. 
Stakori su ostavljeni na privikavanje na prazne kutije za ispitivanje i na okruženje prostorije za ispitivanje ponašanja tijekom jednog sata na dan 1.
grinding the obtained mixture, 
- < mljevenje dobijene mješavine,
The compound of Formula XXXIII can be oxidatively cleaved to form a compound of Formula XXXIV. 
R;-Q Formula XXXI konverziju spoja Formule XXXIII u spoj Formule XXXTV, i
is washed, preferably washed with demineralised water, 
oprano, preporučljivo oprano demineraliziranom vodom,
Generally, these compounds have been found to exhibit excellent inhibition of cell growth against MDR sensitive cancer cell lines. 
Općenito, za ove spojeve je ustanovljeno da pokazuju odlično sprečavanje rasta stanica u odnosu na MDR osjetljivu staničnu liniju tumora.
and at least 50% of the active agent particle material by volume exhibits an optical diameter of 4 µm or less; and one or more species of respirable suspending particles; 
Farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što najmanje 50% čestica glikopirolata kao aktivnog sredstva po volumenu pokazuje optički promjer od 5 µm ili manji.
A bone plate system for securing a bone plate to bone comprising: 
Sustav pločica za kosti za pričvršćivanje pločice za kosti na kost koji obuhvaća: vijak za kosti (600) sa središnjom osi (619);
A compound of any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, for use in treating a condition selected from the group consisting of cardiovascular disease, metabolic conditions, central nervous system conditions, pulmonary conditions, sexual dysfunction, pain and renal dysfunction. 
Spoj u skladu s bilo kojim od paleninih zahtjeva 1 do 17, ili njegova farmaceulski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju stanja koje se bira iz skupine koju čine kardiovaskularna bolest, metabolička stanja, stanja središnjeg živčanog sustava, plućna stanja, spolna disfunkcija, bol i disfunkcija bubrega.
B1, and B2 are independently adenine, guanine, thymine, cytosine, uracil or modified nucleobases. 
B,1iB, su nezavisno adenin, guanin, timin, citozin, uracil ili modificirane nukleobaze.
The pharmaceutical composition for use according to claim 28, wherein said cancer is selected from prostate cancer, renal cancer, hepatic cancer, gastric cancer, thyroid cancer, glioblastoma, Karposi's sarcoma, Castleman's disease, melanoma, cutaneous T-cell lymphoma (CTCL), cutaneous B-cell lymphoma, Sezary syndrome, mycosis fungoides, acute lymphoblastic leukemia, and colorectal cancer. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor izabran od tumora prostate, tumora bubrega, tumora jetre, tumora želuca, tumora štitnjače, glioblastoma, Karposijevog sarkojema, Castlemanove bolesti, melanoma, kožnog limfoma 'T-stanica (CTCL), kožnog Bell limfoma, Sezaryovog sindroma, mycosis fungoides, akutne limfoblastične leukemije, 1 tumora debelog crijeva.
The immunogenic composition according to claim 11 or the vaccine composition according to claim 12, wherein the said immunoadjuvant compound is not covalently linked to the said one or more antigens. 
Imunogeni pripravak u skladu s patentnim zahtjevom 11 ili pripravak cjepiva u skladu s patentnim zahtjevom 12, naznačeni time što navedeni imunoadjuvantni spoj nije kovalentno povezan s navedenim jednim ili više antigena.
Pharmaceutical composition according to Claim 10, characterized in that the said pharmaceutically acceptable ester is formed with physiologically acceptable organic acids chosen from the group comprising acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid. 
Farmaceutski sastav prema zahtjevu 10, naznačen time, da je navedeni farmaceutski prihvatljiv ester stvoren od fiziološki prihvatljivih organskih kiselina odabranih iz skupine koju čine: octena kiselina, askorbinska kiselina, benzojeva kiselina, limunska kiselina, fumarna kiselina, mliječna kiselina, maleična kiselina, metansulfonska kiselina, oksalna kiselina, para-toluensulfonska kiselina, benzensulfonska kiselina, sukcinska kiselina, taninska kiselina i vinska kiselina.
The liquid composition of claim 27, comprising about 0.1-40 mg/ml GCB, about 0.001-10% cysteine, about 1-40% sucrose, at a pH of about 5.5-6.0, and wherein the level of dissolved O2 is less than about 10%. 
Farmaceutska kompozicija prema zahtjevu 24, pri čemu kompozicija sadrži 0,1-40 mg/ml GCB, 0,001-10 % cisteina, 1-40 % saharoze, pH 5,5-6,0, i pri čemu je nivo otopljenog Oz manji od oko 10 %.
In another aspect of the invention, the antibody molecule is an immunoglobulin having a heavy chain comprising or SEQ ID NO: 42, and a light chain comprising SEQ ID NO: 43. 
Molekula protutijela prema zahtjevu 3, naznačena time, da ima jaki lanac koji obuhvaća SEQ ID NO:40, 1 slabi lanac koji obuhvaća SEQ ID NO:35.
Yet another aspect of the invention is a high affinity human AB protofibril selective antibody of subclass IgG1, which has a high affinity for human FcYRI receptors present on microglial cells in the brain. 
Protutijelo ili njegov fragment koji je selektivan i ima visoki afinitet za humane AP protofibrile, pri čemu to protutijelo ili njegov fragment u svojih šest CDR regija ima sljedeće konsenzus sekvence:
Also in other embodiments, the method of selecting a treatment includes excluding or eliminating a treatment, where the presence or absence of the at least one variance is indicative that the treatment will be ineffective or contra-indicated. In other preferred embodiments, in cases in which undesirable side-effects may occur or are expected to occur from a particular therapeutic treatment, the selection of a method of treatment can include identifying both a first and second treatment, where the first treatment is effective to treat the disease or condition, and the second treatment reduces a deleterious effect of the first treatment. 
1 ili 2 kopije rjeđeg alela, G, od rs916758, i 1 ili 2 kopije rjeđeg alela, T, od rs1261134, pri čemu prisutnost navedenog biomarkera ukazuje na povećani rizik za nastanak spomenutog štetnog neurološkog događaja; i odabir prvog postupka liječenja ili odabir drugog postupka liječenja, pri čemu su navedeni prvi postupak liječenja i drugi postupak liječenja ovisni o tome da li je vjerojatno da će navedeni pacijent razviti perifernu neuropatiju kao odgovor na navedeni tretman raka.
The anti-FGFR3 antagonist antibody of any one of claims 14-15, wherein the cancer is a solid tumor, in particular bladder cancer, or multiple myeloma, or wherein the skeletal disorder is selected from the group consisting of achondroplasia, hypochondroplasia, dwarfism, thantophoric dysplasia, and craniosynostosis syndrome. 
Anti-FGFR3 antagonističko protutijelo iz bilo kojeg od patentnih zahtjeva 1-10 za uporabu u skladu s patentnim zahtjevom 15 ili 16, pri čemu je rak solidni tumor, posebice karcinom mjehura, ili multipli mijelom.
The polypeptide of claim 3 or 7, wherein the clotting factor is selected from the group consisting of FVII, FVIIa, FIX, FIXa, FX, and FXa. 
Polipeptid prema patentnom zahtjevu 3 ili 7, naznačen time što je faktor zgrušavanja odabran iz skupine koja se sastoji od FVII, FVIIa, FIX, FIXa, FX, i FXa.
After stirring at room temperature for 1.5 hours, the reaction mixture is re-cooled to 0 °C and treated with 1-bromomethyl-2-chloro-4-ethanesulfonyl-benzene (6.6 g, 22.2 mmol) and sodium iodide (3.3 g, 22.2 mmol). 
Nakon miješanja 1,5 sata pri sobnoj temperaturi, reakcijsku smjesu se ponovno ohladi na OC i pomiješa se s 1-brom-metil-2-klor-4-etansulfonil-benzenom (6,6 g, 22,2 mmola) 1 natrijevim jodidom (3,3 g, 22,2 mmola).
characterized in that no separate adjuvant and/or immune stimulator is added to the composition. 
* nikakva odvojena pomoćna tvar i/ili imuno stimulator nisu dodani u pripravak.
The injector of any one of claims 1 to 18, further comprising a mechanical, electro-mechanical, or electrical input device coupled to the actuator. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, koji dodatno sadrži mehanički ili električni ulazni uređaj spojen s pokretačem (456).
The compound for use of any of claims 1-10, wherein the cancer of the blood or bone marrow is leukemia or lymphoma. 
Tvar za uporabu iz bilo kojeg od patentnih zahtjeva 1-10, pri čemu je rak kože melanom.
The TGFB antagonist for use according to Claim 2, wherein said agent is a protein. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 2, naznačen time što navedeno sredstvo je protein.
A Plasto-ferrite plate as used in example 1 was engraved on a computer-controlled mechanical engraving station with a hollow circle. 
Na ploču izrađenu od Plastoferrita koja je korištena u primjeru 1 ugravira se prsten.
A binding compound according to Claim 1, comprising a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein: 
varijabilnu domenu lakog lanca, ili antigen-vežući fragment istog, koja sadrži CDRL1, CDRL2 i CDRL3, pri čemu:
For parenteral administration, solutions of the novel compounds of the formula (I) in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. 
Za parenteralnu primjenu mogu se rabiti otopine novih spojeva formule (I) u sterilnoj vodenoj otopini, vodenom propilen glikolu, vodenom vitaminu E ili ulju sezama ili kikirikija.